Valeant Pharmaceuticals International Company Profile (NYSE:VRX)

About Valeant Pharmaceuticals International (NYSE:VRX)

Valeant Pharmaceuticals International logoValeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It operates through two segments: Developed markets and Emerging markets. In the Developed Markets segment, it focuses on the areas of dermatology, neurology, gastrointestinal disorders, and eye health therapeutic classes. In the Emerging Markets segment, it focuses on primarily on branded generics, OTC products and medical devices. Its pharmaceutical products include Xifaxan, Solodyn and Glumetza. Its OTC products include PreserVision, Biotrue and Boston. Its other generic products include Latanoprost and Metronidazole. Its ophthalmic surgical products include intraocular lenses, such as Akreos, enVista, Crystalens and Trulign.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NYSE:VRX
  • CUSIP: N/A
  • Web:
  • Market Cap: $4.5 billion
  • Outstanding Shares: 348,521,000
Average Prices:
  • 50 Day Moving Avg: $13.96
  • 200 Day Moving Avg: $13.57
  • 52 Week Range: $8.31 - $24.30
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 3.71
  • P/E Growth: -0.38
Sales & Book Value:
  • Annual Revenue: $9.22 billion
  • Price / Sales: 0.49
  • Book Value: $11.28 per share
  • Price / Book: 1.15
  • EBITDA: $3.75 billion
  • Net Margins: -12.40%
  • Return on Equity: 59.89%
  • Return on Assets: 5.37%
  • Debt-to-Equity Ratio: 6.86%
  • Current Ratio: 1.34%
  • Quick Ratio: 1.10%
  • Average Volume: 11.77 million shs.
  • Beta: -0.36
  • Short Ratio: 1.44

Frequently Asked Questions for Valeant Pharmaceuticals International (NYSE:VRX)

What is Valeant Pharmaceuticals International's stock symbol?

Valeant Pharmaceuticals International trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals International's earnings last quarter?

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) posted its earnings results on Tuesday, August, 8th. The company reported $1.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.97 by $0.08. The company earned $2.23 billion during the quarter, compared to the consensus estimate of $2.23 billion. Valeant Pharmaceuticals International had a negative net margin of 12.40% and a positive return on equity of 59.89%. The firm's quarterly revenue was down 7.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.88) earnings per share. View Valeant Pharmaceuticals International's Earnings History.

Where is Valeant Pharmaceuticals International's stock going? Where will Valeant Pharmaceuticals International's stock price be in 2017?

19 equities research analysts have issued 1-year price targets for Valeant Pharmaceuticals International's shares. Their predictions range from $7.00 to $45.00. On average, they anticipate Valeant Pharmaceuticals International's stock price to reach $17.89 in the next year. View Analyst Ratings for Valeant Pharmaceuticals International.

What are analysts saying about Valeant Pharmaceuticals International stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals International stock:

  • 1. According to Zacks Investment Research, "Once an acquisition giant, Valeant has been caught up in various controversies due to price hike of specialty drugs, erroneous financial reporting and termination of contracts with Philidor Rx Services. After a tumultuous period, Valeant started a rebuilding process with its new CEO, Joseph C. Papa. Even though it is still early to comment on the rebuilding process, but the company’s efforts to sell non-core assets and pay down huge levels of debt is commendable. The company reduced its debt by $4.8 billion and expects to meet its target of $5 billion debt reduction ahead of schedule. The GI business continues to struggle with weak sales of Xifaxan but should see gain in market share with an increased sales force. Valeant trimmed its guidance due to recent divestitures. However, weakness in the dermatology business persists. Shares have underperformed the industry." (10/12/2017)
  • 2. Cantor Fitzgerald analysts commented, "Valeant announced that the FDA confirmed it intends to issue a Voluntary Action Indicated (VAI) inspection classification for its Bausch + Lomb manufacturing facility in Tampa, Florida." (8/16/2017)
  • 3. Royal Bank Of Canada analysts commented, "We have revised our outlook due to the recent VRX financing and accounting treatment for Siliq revenues. While our revenue forecasts have increased due to Siliq, Adj. EBITDA forecasts have declined slightly. Following a modest increase in net debt, our price target declines to $18." (3/23/2017)
  • 4. Deutsche Bank AG analysts commented, "Lowered EPS on higher op ex, interest expense We updated our model following the company's 4Q results and 10-K filing, our meetings with management last week, and to reflect preliminary assumptions for the planned debt refinancing. Overall, we lowered our EPS estimates based primarily on higher spending and interest expense assumptions (see below), which reduced our DCF-derived PT to $19 (from $20). While our target implies material upside from the current stock price, we are sticking with our Hold rating pending greater visibility on improved demand trends for Xifaxan and other core assets, stabilization of the Dermatology business, and further steps to address the debt load and strengthen the balance sheet. We are encouraged that the company has begun to deliver on the expectations that it has set (as of 4Q), a theme we hope to see continue in the quarters ahead." (3/7/2017)
  • 5. Mizuho analysts commented, "The company is using its recently closed sale of assets to L'Oreal to repay $1.1B of a ~2.8% Term A loan due in 2018 (already excluded from our interest rate calculations). The company plans to refinance its existing credit agreement, issue new Term B loans that extend the maturity of current Term B loans due before 2022 (~$4.3B), issue new secured debt, and repay its remaining Term A loan due in April 2020 ($658M). Valeant also plans to repay a portion of its 6.75% secured debt due in 2018 (current balance is $1.59B). In tandem with this exercise, Valeant plans to relax its maintenance covenants in the revolver (currently $875M) and remove the covenants from its Term B loans. While the refinancing is not surprising, it reflects the cloudy outlook on future earnings, in our view." (3/6/2017)

Who are some of Valeant Pharmaceuticals International's key competitors?

Who are Valeant Pharmaceuticals International's key executives?

Valeant Pharmaceuticals International's management team includes the folowing people:

  • Joseph C. Papa, Chairman of the Board, Chief Executive Officer
  • Paul S. Herendeen, Chief Financial Officer, Executive Vice President
  • Christina Ackermann, Executive Vice President, General Counsel
  • Thomas J. Appio, Executive Vice President, Company Group Chairman, International
  • William D. Humphries, Executive Vice President, Company Group Chairman, Dermatology
  • Thomas W. Ross Sr, Lead Independent Director
  • Richard U. DeSchutter, Independent Director
  • Fredric N. Eshelman Pharm.D., Ph.D., Independent Director
  • D. Robert Hale, Independent Director
  • Argeris N. Karabelas Ph.D., Independent Director

Who owns Valeant Pharmaceuticals International stock?

Valeant Pharmaceuticals International's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include PAULSON & COMPANY . INC. (6.00%). Company insiders that own Valeant Pharmaceuticals International stock include Argeris N Karabelas, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Ronald Harold Farmer, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals International.

How do I buy Valeant Pharmaceuticals International stock?

Shares of Valeant Pharmaceuticals International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals International's stock price today?

One share of Valeant Pharmaceuticals International stock can currently be purchased for approximately $12.92.

MarketBeat Community Rating for Valeant Pharmaceuticals International (NYSE VRX)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  1,059 (Vote Outperform)
Underperform Votes:  986 (Vote Underperform)
Total Votes:  2,045
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals International and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Valeant Pharmaceuticals International (NYSE:VRX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 12 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.05)
Consensus Price Target: $17.89 (38.50% upside)
Consensus Price Target History for Valeant Pharmaceuticals International (NYSE:VRX)
Price Target History for Valeant Pharmaceuticals International (NYSE:VRX)
Analysts' Ratings History for Valeant Pharmaceuticals International (NYSE:VRX)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/9/2017Deutsche Bank AGReiterated RatingHold$18.00N/AView Rating Details
10/4/2017HC WainwrightReiterated RatingHold$17.00LowView Rating Details
10/3/2017Canaccord GenuityReiterated RatingHold$16.00LowView Rating Details
9/30/2017Wells Fargo & CompanyReiterated RatingUnderperform$8.00HighView Rating Details
9/28/2017Cantor FitzgeraldReiterated RatingBuy$23.00LowView Rating Details
9/17/2017Piper Jaffray CompaniesReiterated RatingSell$14.00LowView Rating Details
8/29/2017MizuhoReiterated RatingSell$8.00 -> $7.00HighView Rating Details
8/21/2017Stifel NicolausReiterated RatingBuy$45.00MediumView Rating Details
8/10/2017BMO Capital MarketsReiterated RatingMarket Perform$16.00LowView Rating Details
8/10/2017Rodman & RenshawReiterated RatingNeutral$17.00HighView Rating Details
8/10/2017Jefferies Group LLCReiterated RatingBuy$18.00HighView Rating Details
8/9/2017ScotiabankBoost Price TargetSector Perform$14.00 -> $16.00MediumView Rating Details
8/3/2017Royal Bank Of CanadaBoost Price TargetSector Perform -> Sector Perform$19.00 -> $21.00HighView Rating Details
7/17/2017J P Morgan Chase & CoSet Price TargetHold$10.00LowView Rating Details
7/12/2017TD SecuritiesBoost Price TargetHold$15.00 -> $20.00LowView Rating Details
6/17/2017GuggenheimInitiated CoverageBuy$18.00HighView Rating Details
5/23/2017Barclays PLCReiterated RatingHold$20.00LowView Rating Details
5/10/2017BTIG ResearchReiterated RatingNeutralMediumView Rating Details
3/11/2017Morgan StanleyReiterated RatingEqual Weight$17.00 -> $12.00N/AView Rating Details
5/29/2016Susquehanna Bancshares IncReiterated RatingHold$105.00N/AView Rating Details
5/29/2016S&P Equity ResearchReiterated RatingBuyN/AView Rating Details
4/1/2016Citigroup Inc.Reiterated RatingBuyN/AView Rating Details
3/22/2016NomuraReiterated RatingNeutral$60.00N/AView Rating Details
3/15/2016CIBCDowngradeSector Perform -> Sector Underperform$90.00 -> $24.00N/AView Rating Details
12/21/2015Bank of America CorpReiterated RatingBuyN/AView Rating Details
11/23/2015Maxim GroupReiterated RatingHoldN/AView Rating Details
11/2/2015Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$180.00 -> $122.00N/AView Rating Details
10/23/2015Oppenheimer Holdings, Inc.Reiterated RatingMarket PerformN/AView Rating Details
10/19/2015Evercore ISIReiterated RatingBuyN/AView Rating Details
(Data available from 10/16/2015 forward)


Earnings History for Valeant Pharmaceuticals International (NYSE:VRX)
Earnings by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Earnings History by Quarter for Valeant Pharmaceuticals International (NYSE VRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/20176/30/2017$0.97$1.05$2.23 billion$2.23 billionViewListenView Earnings Details
5/9/20173/31/2017$0.87$2.80$2.17 billion$2.11 billionViewListenView Earnings Details
2/28/2017Q416$1.20$1.26$2.34 billion$2.40 billionViewListenView Earnings Details
11/8/2016Q316$1.78$1.55$2.49 billion$2.48 billionViewListenView Earnings Details
8/9/2016Q216$1.48$1.40$2.47 billion$2.42 billionViewN/AView Earnings Details
6/7/2016Q116$1.37$1.27$2.34 billion$2.37 billionViewN/AView Earnings Details
3/15/2016Q415$2.61$2.50$2.75 billion$2.80 billionViewListenView Earnings Details
10/19/2015Q315$2.68$2.74$2.06 billion$2.79 billionViewListenView Earnings Details
7/23/2015Q215$2.46$2.58$2.04 million$2.73 millionViewListenView Earnings Details
4/29/2015Q115$2.34$2.36$1.89 billion$2.20 billionViewN/AView Earnings Details
2/24/2015Q414$2.56$2.58$2.23 billion$2.28 billionViewN/AView Earnings Details
10/20/2014Q314$1.99$2.11$2.06 billion$2.06 billionViewListenView Earnings Details
7/31/2014Q214$1.91$1.91$1.06 billion$1.99 billionViewN/AView Earnings Details
5/8/2014Q114$1.72$1.76$1.04 billion$1.85 billionViewN/AView Earnings Details
2/27/2014Q413$2.06$2.15$986.30 million$2.06 billionViewN/AView Earnings Details
10/31/2013Q313$1.40$1.51$884.14 million$1.54 billionViewN/AView Earnings Details
8/7/2013Q213$1.28$1.34$820.09 million$1.10 billionViewN/AView Earnings Details
5/2/2013Q113$1.25$1.30$1.04 billion$1.07 billionViewN/AView Earnings Details
2/28/2013Q412$1.21$1.34$654.17 million$946.67 millionViewN/AView Earnings Details
11/2/2012Q312$1.13$1.15$875.91 million$884.00 millionViewN/AView Earnings Details
8/2/2012$0.99$1.01ViewN/AView Earnings Details
5/3/2012$0.96$0.99ViewN/AView Earnings Details
11/3/2011$0.57$0.66ViewN/AView Earnings Details
8/4/2011$0.65$0.73ViewN/AView Earnings Details
5/9/2011$0.51$0.56ViewN/AView Earnings Details
2/24/2011$0.45$0.51ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Valeant Pharmaceuticals International (NYSE:VRX)
2017 EPS Consensus Estimate: $3.58
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.94$0.94$0.94
Q2 20171$1.01$1.01$1.01
Q3 20171$0.83$0.83$0.83
Q4 20171$0.80$0.80$0.80
(Data provided by Zacks Investment Research)


Dividend History for Valeant Pharmaceuticals International (NYSE:VRX)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Ownership Percentage: 5.87%
Institutional Ownership Percentage: 50.44%
Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Institutional Ownership by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Insider Trades by Quarter for Valeant Pharmaceuticals International (NYSE:VRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/21/2017Schutter Richard U DeDirectorBuy10,000$14.33$143,300.00View SEC Filing  
5/11/2017Schutter Richard U DeDirectorBuy20,000$13.90$278,000.00View SEC Filing  
3/15/2017Schutter Richard U DeDirectorBuy10,000$10.80$108,000.00View SEC Filing  
3/14/2017Paul HerendeenCFOBuy24,000$10.72$257,280.00View SEC Filing  
3/14/2017Valueact Capital Master Fund,InsiderBuy3,000,000$10.82$32,460,000.00View SEC Filing  
3/13/2017Pershing Square Capital ManageDirectorSell18,114,432$11.00$199,258,752.00View SEC Filing  
12/14/2016Thomas W Sr. RossDirectorBuy5,000$14.73$73,650.00View SEC Filing  
12/12/2016Pershing Square Capital ManageDirectorSell3,476,690$14.85$51,628,846.50View SEC Filing  
8/11/2016Argeris N KarabelasDirectorBuy4,000$24.65$98,600.00View SEC Filing  
6/10/2016Joseph C PapaCEOBuy202,000$24.48$4,944,960.00View SEC Filing  
10/21/2015Ronald Harold FarmerDirectorBuy1,500$181.60$272,400.00View SEC Filing  
7/31/2015Robert L RosielloCFOBuy7,875$254.28$2,002,455.00View SEC Filing  
6/12/2015Robert L RosielloEVPBuy12,900$232.51$2,999,379.00View SEC Filing  
6/9/2015Ronald Harold FarmerDirectorBuy1,000$260.63$260,630.00View SEC Filing  
6/8/2015Ronald Harold FarmerDirectorBuy500$289.20$144,600.00View SEC Filing  
6/2/2015Pavel MirovskyEVPSell38,000$238.01$9,044,380.00View SEC Filing  
5/26/2015Anne Clem WhitakerDirectorBuy7,500$234.67$1,760,025.00View SEC Filing  
5/4/2015Robert Roswell Chai-OnnEVPSell90,938$222.54$20,237,342.52View SEC Filing  
12/10/2014Jeffrey W UbbenInsiderBuy250,000$140.06$35,015,000.00View SEC Filing  
12/3/2014Katharine Berghuis StevensonDirectorBuy1,500$145.73$218,595.00View SEC Filing  
11/24/2014Jeffrey W UbbenInsiderBuy210,000$142.25$29,872,500.00View SEC Filing  
6/23/2014Robert Roswell Chai-OnnEVPSell10,203$121.70$1,241,705.10View SEC Filing  
5/13/2014Robert Roswell Chai-OnnEVPSell10,000$130.08$1,300,800.00View SEC Filing  
4/1/2014Norma Ann ProvencioDirectorSell5,000$132.18$660,900.00View SEC Filing  
3/21/2014Laizer KornwasserEVPBuy2,481$134.97$334,860.57View SEC Filing  
2/3/2014Norma Ann ProvencioDirectorSell5,000$136.23$681,150.00View SEC Filing  
1/24/2014Laizer KornwasserEVPBuy2,536$132.15$335,132.40View SEC Filing  
1/13/2014Norma Ann ProvencioDirectorSell5,000$133.00$665,000.00View SEC Filing  
12/14/2013J. Michael PearsonCEOBuy184,247$81.41$14,999,548.27View SEC Filing  
11/18/2013Laizer KornwasserEVPBuy3,500$107.38$375,830.00View SEC Filing  
11/6/2013Ronald Harold FarmerDirectorBuy1,500$107.98$161,970.00View SEC Filing  
9/13/2013Laizer KornwasserEVPBuy1,000$99.02$99,020.00View SEC Filing  
9/6/2013Norma Ann ProvencioDirectorSell4,000$100.25$401,000.00View SEC Filing  
9/3/2013Norma Ann ProvencioDirectorSell5,000$99.68$498,400.00View SEC Filing  
8/29/2013Fred HassanDirectorBuy51,000$99.01$5,049,510.00View SEC Filing  
8/28/2013Ronald Harold FarmerDirectorBuy2,500$102.36$255,900.00View SEC Filing  
8/23/2013Robert Roswell Chai-OnnEVPBuy5,032$99.30$499,677.60View SEC Filing  
8/12/2013Brian StolzEVPBuy4,500$100.71$453,195.00View SEC Filing  
8/9/2013Laizer KornwasserEVPBuy3,500$100.36$351,260.00View SEC Filing  
6/19/2013G Mason MorfitInsiderBuy1,352,941$85.00$114,999,985.00View SEC Filing  
6/12/2013Lloyd Mitchell SegalDirectorBuy3,190$84.16$268,470.40View SEC Filing  
6/11/2013Norma Ann ProvencioDirectorSell6,000$85.26$511,560.00View SEC Filing  
3/11/2013Laizer KornwasserEVPBuy2,000$70.61$141,220.00View SEC Filing  
11/7/2012Brian M StolzEVPBuy2,040$52.76$107,630.40View SEC Filing  
11/6/2012Howard Bradley SchillerCFOBuy18,300$54.10$990,030.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Valeant Pharmaceuticals International (NYSE:VRX)
Latest Headlines for Valeant Pharmaceuticals International (NYSE:VRX)
DateHeadline logoValeant Pharmaceuticals International, Inc. (VRX) Lowered to "Hold" at Vetr Inc. - October 14 at 4:40 PM logoValeant Pharmaceuticals International Breaks Below 200-Day Moving Average - Notable for VRX - October 14 at 9:17 AM logoValeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bearish Manner : VRX-US : October 13, 2017 - October 13 at 10:02 AM logoValeant Pharmaceuticals International, Inc. (VRX) Downgraded to Sell at Zacks Investment Research - October 12 at 10:22 AM logoValeant Pharmaceuticals International's (VRX) Hold Rating Reaffirmed at Deutsche Bank AG - October 9 at 5:06 PM logoValeant Pharmaceuticals International, Inc. (VRX) Rating Reiterated by HC Wainwright - October 8 at 6:02 PM logoValeant Pharmaceuticals International, Inc. (VRX) Lifted to "Sell" at Vetr Inc. - October 7 at 11:14 PM logoValeant Pharmaceuticals International, Inc. (VRX) Receives Average Recommendation of "Hold" from Brokerages - October 7 at 2:32 AM logoValeant Pharma (VRX) Unit, Solta Medical, Granted FDA 510(k) Clearance for Thermage FLX System - October 6 at 12:38 PM logoValeant Pharmaceuticals International, Inc. – Value Analysis (NYSE:VRX) : October 4, 2017 - October 6 at 12:38 PM logoValeant Pharmaceuticals International, Inc. (VRX) Earns "Hold" Rating from Canaccord Genuity - October 3 at 7:54 PM logoValeant Announces Pricing Of Private Offering Of Senior Secured Notes - MarketWatch - October 3 at 7:40 PM logoValeant Will Release Third-Quarter 2017 Financial Results On November 7 - October 3 at 2:39 PM logoBausch + Lomb Introduces Biotrue® ONEday for Astigmatism Contact Lenses in Europe - October 3 at 2:39 PM logoValeant Pharmaceuticals International, Inc. breached its 50 day moving average in a Bullish Manner : VRX-US : October 3, 2017 - October 3 at 2:39 PM logoValeant: Still Deep in Junk Territory - October 3 at 2:39 PM logoValeant to purchase up to $1B outstanding debt; shares off 1% premarket - October 2 at 8:22 AM logoCorporate News Blog - Valeant Agrees to Sell iNova Pharma; Set to Use Sale Proceeds to Repay Term Loan Debt - October 2 at 8:22 AM logoValeant Commences Cash Tender Offer For $1 Bln Notes; To Also Issue Bonds - October 2 at 8:22 AM logoValeant Announces Launch Of Private Offering Of Senior Secured Notes - October 2 at 8:22 AM logoHead to Head Contrast: Valeant Pharmaceuticals International (VRX) & Its Peers - September 30 at 4:18 PM logoValeant Pharmaceuticals International, Inc. (VRX) Receives "Underperform" Rating from Wells Fargo & Company - September 30 at 2:16 PM logoValeant Pharma (VRX) Completes Sale of iNova Pharmaceuticals to Pacific Equity Partners, Carlyle Group - September 30 at 12:07 PM logoValeant Pharma (VRX) Routine Private Placement Exemption Related to Up to $1.5B in Senior Notes - September 29 at 2:47 PM logoValeant Pharmaceuticals Completes Sale Of iNova Pharmaceuticals To Pacific ... - September 29 at 2:47 PM logoValeant Pharmaceuticals International, Inc. (VRX) Earns "Buy" Rating from Cantor Fitzgerald - September 29 at 2:06 PM logoValeant Pharmaceuticals International, Inc. (VRX) Raised to Sell at Vetr Inc. - September 29 at 12:44 AM logo Brokerages Anticipate Valeant Pharmaceuticals International, Inc. (VRX) Will Announce Earnings of $0.94 Per Share - September 26 at 2:08 PM logoValeant Pharmaceuticals International's (VRX) Hold Rating Reiterated at Deutsche Bank AG - September 25 at 4:44 PM logoTraders Buy High Volume of Put Options on Valeant Pharmaceuticals International (VRX) - September 25 at 8:50 AM logoGlassHouse: NuVasive Using The 'Valeant Playbook' To Deceive Investors - September 19 at 3:27 PM logoValeant Pharmaceuticals International, Inc. (VRX) Stock Rating Reaffirmed by HC Wainwright - September 18 at 10:16 AM logoValeant Commits $200000 to Support Hurricane Relief Efforts - PR Newswire (press release) - September 17 at 9:12 AM logoValeant Pharmaceuticals International's (VRX) Sell Rating Reiterated at Piper Jaffray Companies - September 17 at 8:48 AM logoBuy Amazon, short Valeant among the top picks out of last year's Delivering Alpha - September 12 at 12:01 PM logoToday's Research Reports on Trending Tickers: Endo International and Valeant Pharmaceuticals - September 12 at 12:01 PM logoValeant Pharmaceuticals International, Inc. (VRX) Receives Average Rating of "Hold" from Analysts - September 12 at 3:06 AM logo$2.17 Billion in Sales Expected for Valeant Pharmaceuticals International, Inc. (VRX) This Quarter - September 9 at 3:20 AM logo$20 Should Be Your Cutoff Point - September 8 at 10:06 AM logoNicox first half 2017 business and financial update - September 8 at 2:04 AM logoValeant Pharma's (VRX) Ortho Dermatologics Submits NDA For Psoriasis Treatment IDP-118 - September 7 at 11:00 AM logoBetter Buy: Valeant Pharmaceuticals International, Inc. vs. Rite Aid Corporation - Motley Fool - September 4 at 7:47 AM logoValeant Pharmaceuticals International, Inc. (VRX) Receives Buy Rating from Cantor Fitzgerald - August 29 at 4:46 PM logoValeant Pharmaceuticals International, Inc. (VRX) Given "Underperform" Rating at Mizuho - August 29 at 1:04 PM logoShort Interest in Valeant Pharmaceuticals International, Inc. (VRX) Grows By 37.6% - August 29 at 1:56 AM logoValeant Pharmaceuticals International, Inc. (VRX) Rating Lowered to Sell at Vetr Inc. - August 27 at 1:08 PM logoETFs with exposure to Valeant Pharmaceuticals International, Inc. : August 25, 2017 - August 26 at 12:05 AM logoImmune Design’s quest for a cancer vaccine could go the distance - August 25 at 3:34 PM logoInsider Buying: Valeant Pharmaceuticals International, Inc. (VRX) Director Acquires 10,000 Shares of Stock - August 22 at 7:34 PM logo3 Reasons You Should Be Wary of Valeant Pharmaceuticals Intl Inc. - August 22 at 7:46 AM



Valeant Pharmaceuticals International (VRX) Chart for Monday, October, 16, 2017

This page was last updated on 10/16/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.